top of page

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma


This is a research study for a new treatment for liver cancer. The trial is designed to compare the effectiveness of a three-drug combination with a placebo in patients with untreated liver cancer. The three drugs being studied are atezolizumab, bevacizumab, and tiragolumab. Atezolizumab is an immune checkpoint inhibitor, bevacizumab targets a protein that helps tumors grow new blood vessels, and tiragolumab is an investigational drug that is thought to work by stimulating the immune system to fight cancer.

Placebo: A placebo is a substance or treatment that has no active medical properties but is given to a patient as if it were a real medication or treatment. It is often used in medical research to compare the effects of a new drug or treatment with the effects of no treatment at all. The idea is to see if the new drug or treatment is genuinely effective by comparing how patients who receive the real treatment fare compared to those who receive the placebo

Immune checkpoint inhibitor: The immune system can help fight cancer. Drugs called “checkpoint inhibitors” work by releasing a natural brake on your immune system so that immune cells can recognize and attack tumors.

For more information about the trial, click the link below:

Clinical Trial Site: Einstein


To see all available clinical trials click here.



Recent Posts

See All

NCI-2019-07694

Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2) This is a research study called NAPOLI-2. It is designed to see

NCT05908786

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT IMMUNOTHERAPY COMBINATIONS IN PATIENTS WITH SURGICALLY RESECTABLE HEPATOCELLULAR CAR

NCI-2017-01380

OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy This research study is investigating a drug called

コメント


bottom of page